BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11782375)

  • 1. Tumor-targeted gene therapy for nasopharyngeal carcinoma.
    Li JH; Chia M; Shi W; Ngo D; Strathdee CA; Huang D; Klamut H; Liu FF
    Cancer Res; 2002 Jan; 62(1):171-8. PubMed ID: 11782375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells.
    Wang H; Zhao Y; Zeng L; Tang M; El-Deeb A; Li JJ; Cao Y
    Anticancer Res; 2004; 24(1):67-74. PubMed ID: 15015577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy.
    Chia MC; Shi W; Li JH; Sanchez O; Strathdee CA; Huang D; Busson P; Klamut HJ; Liu FF
    Mol Ther; 2004 Jun; 9(6):804-17. PubMed ID: 15194047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minicircle-oriP-IFNγ: a novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma.
    Zuo Y; Wu J; Xu Z; Yang S; Yan H; Tan L; Meng X; Ying X; Liu R; Kang T; Huang W
    PLoS One; 2011 May; 6(5):e19407. PubMed ID: 21573215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
    Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
    Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma.
    Weinrib L; Li JH; Donovan J; Huang D; Liu FF
    Cancer Gene Ther; 2001 May; 8(5):352-60. PubMed ID: 11477455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minicircle-oriP-miR-31 as a Novel EBNA1-Specific miRNA Therapy Approach for Nasopharyngeal Carcinoma.
    Wu J; Tan X; Lin J; Yuan L; Chen J; Qiu L; Huang W
    Hum Gene Ther; 2017 May; 28(5):415-427. PubMed ID: 28042945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of nasopharyngeal carcinoma growth by RTA-expressing baculovirus vectors containing oriP.
    Wang L; Shan L; Lo KW; Yin J; Zhang Y; Sun R; Zhong J
    J Gene Med; 2008 Oct; 10(10):1124-33. PubMed ID: 18642396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential efficacy of p16 gene therapy for EBV-positive nasopharyngeal carcinoma.
    Li AA; Ng E; Shi W; Lee A; Chia M; Liu TJ; Huang D; O'Sullivan B; Gullane P; Liu FF
    Int J Cancer; 2004 Jun; 110(3):452-8. PubMed ID: 15095314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Berberine inhibits the proliferation of human nasopharyngeal carcinoma cells via an Epstein-Barr virus nuclear antigen 1-dependent mechanism.
    Wang C; Wang H; Zhang Y; Guo W; Long C; Wang J; Liu L; Sun X
    Oncol Rep; 2017 Apr; 37(4):2109-2120. PubMed ID: 28259949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential utility of BimS as a novel apoptotic therapeutic molecule.
    Yip KW; Li A; Li JH; Shi W; Chia MC; Rashid SA; Mocanu JD; Louie AV; Sanchez O; Huang D; Busson P; Yeh WC; Gilbert R; O'sullivan B; Gullane P; Liu FF
    Mol Ther; 2004 Sep; 10(3):533-44. PubMed ID: 15336653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies.
    Sivachandran N; Sarkari F; Frappier L
    PLoS Pathog; 2008 Oct; 4(10):e1000170. PubMed ID: 18833293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress of EBNA1/oriP-based plasmid applied in gene therapy].
    He J; Zhang ZQ
    Sheng Wu Gong Cheng Xue Bao; 2005 May; 21(3):507-10. PubMed ID: 16108385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of targeted FasL in nasopharyngeal carcinoma.
    Li JH; Shi W; Chia M; Sanchez-Sweatman O; Siatskas C; Huang D; Busson P; Klamut H; Yeh WC; Richardson C; O'Sullivan B; Gullane P; Neligan P; Medin J; Liu FF
    Mol Ther; 2003 Dec; 8(6):964-73. PubMed ID: 14664799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EBV replicon vector system enhances transgene expression in vivo: applications to cancer gene therapy.
    Otomo T; Yamamoto S; Morishita R; Kaneda Y
    J Gene Med; 2001; 3(4):345-52. PubMed ID: 11529664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GAP31 from an ancient medicinal plant exhibits anti-viral activity through targeting to Epstein-Barr virus nuclear antigen 1.
    Shen CL; Huang WH; Hsu HJ; Yang JH; Peng CW
    Antiviral Res; 2019 Apr; 164():123-130. PubMed ID: 30817940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An enhanced EBNA1 variant with reduced IR3 domain for long-term episomal maintenance and transgene expression of oriP-based plasmids in human cells.
    Wendelburg BJ; Vos JM
    Gene Ther; 1998 Oct; 5(10):1389-99. PubMed ID: 9930345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia.
    Judde JG; Spangler G; Magrath I; Bhatia K
    Hum Gene Ther; 1996 Mar; 7(5):647-53. PubMed ID: 8845390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy.
    Mocanu JD; Yip KW; Alajez NM; Shi W; Li JH; Lunt SJ; Moriyama EH; Wilson BC; Milosevic M; Lo KW; van Rooijen N; Busson P; Bastianutto C; Liu FF
    Mol Ther; 2007 May; 15(5):921-9. PubMed ID: 17356543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1.
    Nasimuzzaman M; Kuroda M; Dohno S; Yamamoto T; Iwatsuki K; Matsuzaki S; Mohammad R; Kumita W; Mizuguchi H; Hayakawa T; Nakamura H; Taguchi T; Wakiguchi H; Imai S
    Mol Ther; 2005 Apr; 11(4):578-90. PubMed ID: 15771960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.